(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
What's Your Number one Superhuman Film Made? - 2NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- 3Why some African countries are prone to military takeovers
- 4Opening Potential: Self-awareness and Long lasting Learning
- 5An Extended period of Voyaging Carefully: the World with Reason
- The Most Vital Crossroads in Olympic History
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Manual for Famous Beverages 2024
- Dependable Savvy Locks to Update Your Home Security
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- ‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- France will build a new aircraft carrier as it increases defense spending
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
